Full Program - ISCT 2024

Message Image

Skip main navigation (Press Enter).

ISCT 2024 RECORDINGS NOW AVAILABLE

Click on the Access Now button and log in with
your ISCT account.

Access to recordings is determined by your ISCT 2024 registration type.

DOWNLOAD
FULL DIGITAL PROGRAM

The Full Program provides you with a robust preview of all event sessions you can experience at ISCT 2024 in Vancouver, Canada.

Explore a selection of exclusive ISCT programs tailored to immerse you in the latest advancements in cell and gene therapy.

Translational Pathway Program
25 plenary and concurrent sessions in which global key opinion leaders are invited to present novel research, data, and ideas that will shape the future of the cell and gene therapy translation sector.

Roundtable Program
50 workshop-like sessions that leverage the interdisciplinarity and depth in expertise of ISCT delegates to tackle pressing practical problems facing the cell and gene therapy translation sector and provide a platform to collaborate on timely practical solutions.

Global Showcase Presentations
Fast-paced and engaging presentations that provide a platform for ISCT partners to showcase their distinctive features, cutting-edge products, and innovative technologies.

Corporate Sessions
Educational sessions organized by ISCT partners to explore important topics and emerging trends within the rapidly evolving landscape of cell and gene therapy.

VIEW THE FULL PROGRAM FOR:

TUESDAY, MAY 28, 2024

WEDNESDAY, MAY 29, 2024

07:00

07:00-08:00

CORPORATE SESSION

Improving Cell and Gene Therapy Manufacturing Processes by Automated On-Line and In-Line Bioprocess Analytical Technologies

08:00

08:00–09:00
GLOBAL CGT MARKETS

Japan's 10-Year Experience in Regulating Clinical Access for Unapproved and Unproven Cell Therapies: A Model for Other Markets?

08:00–09:0
BIOPROCESSING & MANUFACTURING

Managing the First Mile from Collection to Cryopreservation: Standardizing Starting Material Requirements

08:00–09:00
BASIC AND DISCOVERY RESEARCH

Converting Skeptics: Understanding the Fundamentals of MSC Biology

08:00–09:00
BIOPROCESSING & MANUFACTURING

Revolutionizing Patient Access: Disrupting the Delivery of Cell Therapies

08:00–09:00
REGULATION & POLICY

Are Shared Platforms Part of the Future of Product Development?

08:00–09:00
BIOPROCESSING & MANUFACTURING

Can Process Analytical Technologies (PATs) Really Improve Your CGT Manufacturing Process?

SUPPORTED BY:

09:00

09:30

09:15–10:15
BIOPROCESSING & MANUFACTURING

Revolutionizing Healthcare: Mayo Clinic Breakthrough Technologies for Patient-Centric Cures

09:15–10:15
CLINIC & THERAPEUTIC DEVELOPMENT

Managing the Final Mile: Preparing Hospitals for Widespread CGT Product Integration

09:15–10:15
CLINIC & THERAPEUTIC DEVELOPMENT

MSCs in the Clinic: A Post-Mortem Examination

09:15–10:15
REGULATION & POLICY

Point-of-Care Manufacturing: Does Improving Patient Access Increase their Risks?

09:15–10:15
REGULATION & POLICY

Demonstrating Comparability: Are Potency Assays Necessary?

09:15–10:15
TOOLS & TECH

Industry 4.0: What is the Future Role of Process Analytical Tools (PATs)?

10:00

10:15-10:45

COFFEE BREAK

10:45–11:45
WORKFORCE DEVELOPMENT

Expanding Cell Therapy Clinical Trials to Community Health Centers: Training Healthcare Providers

10:45–11:45
BIOPROCESSING & MANUFACTURING

Minimizing Risks, Maximizing Speed: Streamlining Your Supply Chain from Research to Rollout

10:45–11:45
CLINIC & THERAPEUTIC DEVELOPMENT

Back to the Future: Setting up MSC Clinical Trials for Success

10:45–11:45
BIOPROCESSING & MANUFACTURING

Enabling Point-of-Care Manufacturing: The Need to Improve QC Assays

10:45–11:45
REGULATION & POLICY

Overcoming Regulatory Hurdles to Product Platforms: Leveraging Pre-Clinical Studies Effectively

10:45–11:45
BIOPROCESSING & MANUFACTURING

Elevating Cell Therapy Manufacturing Using Industry 4.0: Unlocking Total Patient Access for Life-Saving Therapies

11:00

11:45-13:00

LUNCH
in Level 2

12:00

12:00-13:00

ELEVATOR
PITCHES

12:00-13:00

CORPORATE SESSION

Manufacturing Brighter Futures—Introducing the Next Generation of CGT Manufacturing Technology

12:00-13:00

CORPORATE SESSION

Sonoma Biotherapeutics' Cell Sorter Experience in Isolation of TReg Cells - Incorporating the CGX10 Cell Isolation System

13:00

13:00–14:00
REGULATION & POLICY

Are CAR-Ts Safe? Investigating the Magnitude of the Risks

13:00–14:00
BIOPROCESSING & MANUFACTURING

How Low Can We Go? Reducing Risks in Cold Chain Management

13:00–14:00
BIOPROCESSING & MANUFACTURING

Preparing for Off the Shelf: Accelerating Allogeneic iPSC Therapies

SUPPORTED BY:

13:00–14:00
CLINIC & THERAPEUTIC DEVELOPMENT

Secretome, Native EVs, or Engineered EVs: What's the Best Cell-Free Cell Therapy?

13:00–14:00
REGULATION & POLICY

Preparing for AI: Anticipating Regulatory Challenges

14:00

14:15–15:15
CLINIC & THERAPEUTIC DEVELOPMENT

Autoimmune Diseases: Can CAR-Directed Cell Therapies Become Standard of Care?

14:15–15:15
BIOPROCESSING & MANUFACTURING

Post-Thaw Viability Testing: The Controversy, The Implementation, The Possibilities

14:15–15:15
TOOLS & TECH

mRNA Therapeutics: You’re Simply the Best, Better Than All the Rest

14:15–15:15
REGULATION & POLICY

Accelerating iPSC-based Therapeutic Development: The Case for Harmonizing Regulatory Requirements

14:15–15:15
REGULATION & POLICY

Contributing to FDA's Standards Recognition Program for Regenerative Medicine Therapies (SRP-RMT)

14:15–15:15
TOOLS & TECH

Preparing for AI: Building Tools for -Omics Analysis and Biomarker Determination

15:00

15:15-15:45

COFFEE BREAK

15:00-16:30

CORPORATE SESSION

Market success for cell and gene therapies – solving challenges when translating novel cellular therapies into commercial scale

16:00

16:15-17:00

WELCOME ADDRESS & MAJOR AWARDS PRESENTATION

17:00

17:00-18:30

18:00

18:30

18:30-20:30

WELCOME RECEPTION

in Exhibit Hall

SUPPORTED BY:

19:00-20:30

POSTER NETWORKING RECEPTION 1

Process Development and Manufacturing

Immunotherapy (CAR-T, T Reg, NK Cells, etc.)

Gene Editing / Gene Therapies

GLOBAL SHOWCASE
Theatre A

18:45-19:00
The CFU Assay: An established tool facilitating the realization of
next generation therapies
Learn More →

19:00-19:15
New GMP Reagents for Reliable Cell Activation and Expansion in T
Cell Therapy Development and Manufacturing
Learn More →

19:15-19:30
Synthetic Peptide Growth Factors: Bringing Innovation to Cell Therapy and Regenerative Medicine
Learn More →

GLOBAL SHOWCASE
Theatre B

18:45-19:00
Importance of CAR-T cell therapy quality control throughout the patient's journey
Learn More →

19:00-19:15
Ensuring Regulatory Compliance in Cell Therapies from Lab to Bedside
Learn More →

19:15-19:30
Future-Proof Bio-decontamination in Your Cell and Gene Therapy Process and Facility
Learn More →

19:00

19:30

20:00

21:00

THURSDAY, MAY 30, 2024

07:00

07:30

07:00-08:00

Redefining Sustainability in CGT: Ensuring Affordability and Accessibility through Strategic Innovations

CORPORATE SESSION

08:00

08:30

08:00–09:00
SCIENCE & INNOVATION

CONCURRENT

MSC Route of Delivery

08:00–09:00
SCIENCE & INNOVATION

CONCURRENT

Advanced Techniques for Regenerative Medicine

08:00–09:00
ORAL ABSTRACT

Immunotherapy (CAR-T, T Reg, NK Cells etc.)

08:00–09:00
TOOLS & TECH

Enabling Patient Access: Identifying Disruptive Technologies in CGT

08:00–09:00
TOOLS & TECH

Innovation in Immunity: Accelerating T-Cell Recovery in Allogeneic HSCT

08:00–09:00

PITCH SESSION 1

09:00

09:30

09:15–10:15
SCIENCE & INNOVATION

CONCURRENT

Extracellular Vesicles: Potential Tools for Targeted Gene Editing In Vivo

09:15–10:15
SCIENCE & INNOVATION

CONCURRENT

Beyond the Dead (MSCs)

09:15–10:15
SCIENCE & INNOVATION

CONCURRENT

Emerging Technologies in Cell Therapy

09:15–10:15
ORAL ABSTRACT

Immunotherapy (CAR-T, T Reg, NK Cells etc.)

09:15–10:15
COGS & BUSINESS MODELS

ROUNDTABLE

The Third-Party Service Provider: Unavoidable Necessity or Powerful Partner?

09:15–10:15
COGs & BUSINESS MODELS

ROUNDTABLE

Strategizing CGT Fundraising: Unlocking Opportunities in Today's Capital Market

10:00

10:30

10:15-10:45

COFFEE BREAK
in Exhibit Hall

SUPPORTED BY:

GLOBAL SHOWCASE
Theatre A

10:15-10:30
Overcoming cell processing challenges in advanced therapies with Ksep50®
Learn More →

10:30-10:45
The Power of Small-Scale Parallel Bioreactor Systems in Cell Therapy Development
Learn More →

GLOBAL SHOWCASE
Theatre B

10:15-10:30
Problems Using Enzymes for Isolating/Recovering Cells? VitaCyte Has Answers.
Learn More →

10:30-10:45
Automated & closed manufacturing of engineered NK cell therapies
Learn More →

10:45-12:15

11:00

11:30

12:00

12:30

12:15-13:45

LUNCH
in Exhibit Hall

12:45-13:45

CORPORATE SESSION

CAR-T Expansion Data and Pre-/Post-Thaw Analysis

12:45-13:45

CORPORATE SESSION

Overcoming Cell Therapy Manufacturing Challenges with Automation, Scalability, and Process Flexibility

GLOBAL SHOWCASE
Theatre A

12:15-12:30
Solutions for gene engineering of hematopoietic stem cells in an automated and functionally closed system
Learn More →

12:30-12:45
Engineered Innovation: The Making-of DENARASE® High Salt for high-efficiency DNA removal in viral vector manufacturing
Learn More →

12:45-13:00
Robust characterization assays enable efficient GMP production of ribonucleoprotein complexes.
Learn More →

13:00-13:15
Improving Affordability and Access of CAR-T Cell and Other Gene Modified Cell Therapies
Learn More →

13:15-13:30
New Containment solutions for automated aseptic filling for gene therapy
Learn More →

13:30-13:45
An Introduction of the Cytiva New, End-to-End Solution to Manufacture Autologous CAR-T Therapies at Commercial Scale
Learn More →

GLOBAL SHOWCASE
Theatre B

12:15-12:30
Building Innovation Districts with Mayo Clinic
Learn More →

12:30-12:45
Toolbox for iPS cell-based therapy: GMP iPSC lines, enhanced gene editing, new protocols for MSC, cardiac, as well as RPE induction, and novel feeder-free NK differentiation / expansion platform
Learn More →

12:45-13:00
BioCentriq: Delivering Hope
Learn More →

13:00–13:15
CD34+ Hematopoietic Stem/Progenitor Cell Enumeration in Apheresis Collections Using a New Microfluidic Cartridge-Based Flow Cytometry Platform
Learn More →

13:15-13:30
Partnering for Progress: Cell and Gene Therapy's Integrated Business Model 2.0
Learn More →

13:30-13:45
End-to-End Solution for Decentralized / Point-of-Care Manufacturing: Technical and Business Advancements to Make it Happen
Learn More →

13:00

13:30

13:45-15:15

14:00

14:30

15:00

15:30

15:15-15:45

COFFEE BREAK
in Exhibit Hall

SUPPORTED BY:

GLOBAL SHOWCASE
Theatre A

15:15-15:45
Innovative 3D In Vitro Platforms to Create Scalable Human iPSC-derived 3D Engineered Skeletal Muscle & Cardiac Tissue Models for Drug Discovery
Learn More →

GLOBAL SHOWCASE
Theatre B

15:15-15:45
Delivering on Autoimmune Potential Will Require Significant Changes in How Cell Therapy is Delivered
Learn More →

15:45–16:45
TRANSLATION TO CLINIC

CONCURRENT

Accelerating Your Product Timeline to Market by Keeping Up with Process Development Advancements

15:45–16:45
TRANSLATION TO CLINIC

CONCURRENT

Over-Looked and Under-Appreciated Non-MSC Exosomes

15:45–16:45
TRANSLATION TO CLINIC

CONCURRENT

Purposeful Cellular and Microbiome Engineering - not just CAR-Ts

15:45–16:45
ORAL ABSTRACT

Chief Scientific Officer Abstract Showcase

15:45–16:45
REGULATION & POLICY

Emerging Shadow Markets in CGT, Can You Protect Your Patients From Unproven Therapies?

15:45–16:45
COGs & BUSINESS MODELS

Investor Temperature Check: What’s Hot and What’s Not in CGT

16:00

16:30

17:00-18:00
TRANSLATION TO CLINIC

The State of iPSC-Derived Cell Therapies and Accelerating Clinical POC

17:00-18:00
TRANSLATION TO CLINIC

Entering the MSC 2.0 Era: MSCs as Cellular Building Blocks for Next Generation Therapies

17:00-18:00
ORAL ABSTRACT

Late Breaking Session

17:00–18:00
CLINIC & THERAPEUTIC DEVELOPMENT

Preventing GVHD: T-Cell Depletion versus Post-Transplant Cyclophosphamide

17:00–18:00
COGs & BUSINESS MODELS

CGT Matchmaking: Finding the Right Partner

17:00

17:30

18:00

18:30

18:00-19:00

CORPORATE SESSION

Deliver What's Next: Fueling the Future of Autologous CAR-T Therapy

18:00-19:30

POSTER NETWORKING
RECEPTION 2

Process Development and Manufacturing

Immunotherapy (CAR-T, T Reg, NK Cells, etc.)

Gene Editing / Gene Therapies

GLOBAL SHOWCASE
Theatre A

18:00-18:15
A Novel, Microfluidics Approach to Advance Innovative Cell Therapy Manufacturing
Learn More →

18:15-18:30
Mycoplasma Testing and Validation Strategies for Cell and Gene Therapies
Learn More →

GLOBAL SHOWCASE
Theatre B

18:00-18:15
cGMP-Grade MAD7 TARGATT TM Master iPSCs for Allogenic Cell Therapies
Learn More →

19:00

19:00-22:30

GLOBAL INDUSTRY NETWORKING RECEPTION

(by invitation only)

19:30-21:30

EARLY STAGE PROFESSIONAL (ESP)
NETWORKING RECEPTION

(by invitation only)

22:30

FRIDAY, MAY 31, 2024

06:00

06:00-08:00

SUPPORTED IN PART BY:

07:00-08:00

CORPORATE SESSION

Challenges of Scalable Manufacturing of Allogeneic Cell Therapies

08:00

08:30

08:00–09:00
FROM FIH TO CLINICAL ACCELERATION

CONCURRENT

The Cutting-Edge of Stem Cell Genetic Innovation

08:00–09:00
FROM FIH TO CLINICAL ACCELERATION

CONCURRENT

Unlocking the Value of your Clinical Study

08:00–09:00
ORAL ABSTRACT

Mesenchymal Stem / Stromal Cells

08:00–09:00
GLOBAL CGT MARKETS

The Rise of Asia Pacific: Learning From the Region's Leaders and Innovators

08:00–09:00
COGS & BUSINESS MODELS

Protecting Your Brand in a New Market: How to Build a Global IP Strategy?

09:00

09:30

09:15–10:15
FROM FIH TO CLINICAL ACCELERATION

CONCURRENT

Accelerated Approvals: The Viability of Surrogate Endpoints

09:15–10:15
FROM FIH TO CLINICAL ACCELERATION

CONCURRENT

From Attackers to Allies: Engineering Cells to Quench the Autoimmune Inferno

09:15–10:15
FROM FIH TO CLINICAL ACCELERATION

CONCURRENT

Enabling Gene Editing Platforms for Novel In Vivo and Ex Vivo Therapeutics

09:15–10:15
ORAL ABSTRACT

Process Development and Manufacturing

09:15–10:15

PITCH SESSION 2

09:15–10:15
REGULATION & POLICY

Ultra Rare Disease: Is Perpetual IND a Regulatory Solution for Access?

09:15–10:15
REGULATION & POLICY

The Post-Marketing Authorization Elephant in the Room: Who Pays the Bill?

10:00

COFFEE BREAK
in Exhibit Hall

10:15-10:45

GLOBAL SHOWCASE
Theatre A

10:15-10:45
Advanced Therapies 2.0: Manufacturing and Supply Chain Considerations for the 21st Century
Learn More →

GLOBAL SHOWCASE
Theatre B

10:15-10:30
Smart Quality Testing for Unique Cell and Gene Therapy Challenges
Learn More →

10:30-10:45
Fully Automated One-Hour Mycoplasma Testing for Products Containing Mammalian Cells Using a Molecular Lab-In-a-Pouch Closed System
Learn More →

10:30

10:45-12:15

11:00

12:00

12:15-13:45

LUNCH
in Exhibit Hall

12:15-12:45

ANNUAL GENERAL MEETING (AGM)

Society Business Meeting

12:45-13:45

CORPORATE SESSION

Gene Editing in Hematopoietic Stem Cells

12:45-13:15

CORPORATE SESSION

Combining Automation and Defined Culture Conditions to Enable Rapid Manufacturing of Robust CAR-T Cell Products

13:15-13:45

CORPORATE SESSION

Two Distinct Activation Methods Yield Clinical-Scale Expansion of γδ T Cells

GLOBAL SHOWCASE
Theatre A

12:15-12:30
The Critical Last Step That’s Often Overlooked First: Closing and Automating Cryopreservation Applications
Learn More →

12:30-12:45
A Scalable Precision Delivery Platform for High Efficiency, High Viability ex-vivo Delivery into Difficult-To-Transfect Cells Using Silicon Nanoneedles
Learn More →

12:45-13:00
Large-scale Expansion of Human Mesenchymal Stem/Stromal Cells in Xeno-free conditions
Learn More →

13:00-13:15
ARM-X: Putting Pedal to the Metal for the Design of Cell-Based Anti- Cancer Vaccines
Learn More →

13:15-13:45
Establishing large-scale cell manufacturing technology for mesenchymal stem cells using novel dissolvable microcarriers in 50L bioreactors
Learn More →

GLOBAL SHOWCASE
Theatre B

12:15-12:30
Bionic, scalable & brand new!” – The New Bioreactor for Cell Therapy Manufacturing
Learn More →

12:30-12:45
Ex Vivo Engineering of Primary Cells Using RNA-Lipid Nanoparticles and Scale-Up Manufacturing for Cell and Gene Therapies
Learn More →

12:45-13:00
Advancing Autologous CAR-T Cell Therapy from Tech Transfer to Clinical Manufacturing
Learn More →

13:00-13:30
CAR-T manufacturing workflow in stirred-tank bioreactors for allogeneic production
Learn More →

13:30-13:45
Overcoming Evolving Training Needs: Empowering Labs For Long-Term Success Through Our CGT Professional Learning Journey Approach
Learn More →

13:00

13:30

13:45-15:15

14:00

15:00

15:30

COFFEE BREAK
in Exhibit Hall

15:15-15:45

15:45–16:45
LAUNCH AND PATIENT ACCESS

CONCURRENT

Industrializing Manufacturing & Distribution

15:45–16:45
LAUNCH AND PATIENT ACCESS

CONCURRENT

Value and Reimbursement

15:45–16:45
LAUNCH AND PATIENT ACCESS

CONCURRENT

Reimagining Patient Access

15:45–16:45
ORAL ABSTRACT

Gene Editing / Gene Therapies

15:45–16:45
CLINIC & THERAPEUTIC DEVELOPMENT

Trendsetting in Scientific Journals: Who Will Publish The Next Breakthrough?

15:45–16:45
CLINIC & THERAPEUTIC DEVELOPMENT

Designing a Cell Therapy Clinical Trial for Acute Care Indications: Resolving the Paradox

16:00

17:00

17:00-18:00
LAUNCH AND PATIENT ACCESS

Are In Vivo Cell Therapies the Future?

17:00-18:00
LAUNCH AND PATIENT ACCESS

Rare Diseases and Patient Access – The Mission and The Challenges

17:00-18:00
ORAL ABSTRACT

Exosomes / EVs

17:00–18:00
REGULATION & POLICY

Integrating Sustainability Into CGT, Working Towards a Greener Future

SUPPORTED BY:

17:00–18:00
REGULATION & POLICY

Viral Versus Non-Viral: What's the Better Vector?

SUPPORTED BY:

17:00–18:00

CORPORATE SESSION

Streamlining Your Path to Market: Leveraging the Latest CAR-T Technologies and Enabling Tools

18:00

19:00

19:00-23:30

ISCT GALA EVENT

Celebrating 30 Years of ISCT Meetings

Separate Registration Required

23:30

SATURDAY, JUNE 1, 2024

07:00

07:30

08:00

08:30

08:00-15:30

Cell Therapy Manufacturing: Strategy& Optimization

08:00–08:30
Registration

08:30–15:30
Track One
Investigational CGT Products: Development Strategy and Optimization

08:30–15:30
Track Two
Commercialized CGT Products: Overcome Challenges in Developing and Manufacturing

08:45-09:45

Early Stage Professionals (ESPs) Mentoring Summit 2024

10:00-13:00

Mastering the Art of Scientific Writing and Reviewing in an AI-Integrated World

07:30-16:00

iPSC

iPSCs: From Bench to Bedside

Pre-Registration Only

07:30–08:00
Check-In & Coffee

08:00
Program Begins

08:30-16:00

EXOSOMES

MSC-EVs: Paving the Road to Regulatory Approval

Pre-Registration Only

08:30–09:00
Check-In & Coffee

09:00
Program Begins

09:00

09:00–10:00
WORKFORCE DEVELOPMENT

Addressing Urgent Training Needs: Building a Standardized Training Program for a Growing Workforce

09:00–10:00
BIOPROCESSING & MANUFACTURING

Let's Talk Particulates: Working Towards Best Practices

SUPPORTED BY:

09:30

10:00

10:15–11:15
BIOPROCESSING & MANUFACTURING

Learning From Those Who Have Done It: Dos and Don'ts When Expanding Your GMP Lab

SUPPORTED BY:

10:15–11:15
GLOBAL CGT MARKETS

Working Towards Global Patient Access: Emerging Markets in Cell and Gene Therapy

10:30

11:00

11:30

11:30–12:30
REGULATION & POLICY

Beyond BMT: Regulating Your Lab's Cell Therapies Across Medical Specialties

12:00

12:30

16:00

16:30

16:00-17:30

SCIENTIFIC SIGNATURE SERIES JOINT NETWORKING RECEPTION

SEE YOU SOON AT THE ISCT EUROPE 2024 REGIONAL MEETING

SEE YOU NEXT YEAR AT THE ISCT 2025 NEW ORLEANS ANNUAL MEETING

Powered by Higher Logic